What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis
Authors
Keywords
Proprotein convertase subtilisin/kexin type 9, Polymorphisms, Cardiovascular risk, Lipids, Meta-analysis
Journal
Lipids in Health and Disease
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-06-12
DOI
10.1186/s12944-017-0506-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genetic susceptibility to cerebrovascular disease
- (2016) David Della-Morte et al. CURRENT OPINION IN LIPIDOLOGY
- The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy
- (2016) Q Feng et al. PHARMACOGENOMICS JOURNAL
- E670G polymorphism of PCSK9 gene of patients with coronary heart disease among Han population in Hainan and three provinces in the northeast of China
- (2016) Xi-Min He et al. Asian Pacific Journal of Tropical Medicine
- Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
- (2015) Rainer Schulz et al. BASIC RESEARCH IN CARDIOLOGY
- The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis
- (2015) Amélie Bonnefond et al. DIABETOLOGIA
- Genetic variation and gastric cancer risk: a field synopsis and meta-analysis
- (2015) Simone Mocellin et al. GUT
- PCSK9: A key factor modulating atherosclerosis
- (2015) Sha Li et al. Journal of Atherosclerosis and Thrombosis
- Combined PCSK9 and APOE Polymorphisms are Genetic Risk Factors Associated with Elevated Plasma Lipid Levels in a Thai Population
- (2015) Nutjaree Jeenduang et al. LIPIDS
- The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis
- (2015) Gaojun Cai et al. Lipids in Health and Disease
- The Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-Analysis
- (2015) Anthony Au et al. Scientific Reports
- PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial Hypercholesterolemia
- (2014) Yascara Grisel Luna Saavedra et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9 gene mutations and low-density lipoprotein cholesterol
- (2014) Na-Qiong Wu et al. CLINICA CHIMICA ACTA
- PCSK9 and LDLR degradation
- (2014) Thomas A. Lagace CURRENT OPINION IN LIPIDOLOGY
- Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects
- (2014) Jacqueline M. Anderson et al. Journal of Clinical Lipidology
- Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort
- (2014) Afef Slimani et al. JOURNAL OF MOLECULAR NEUROSCIENCE
- Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins
- (2014) Iris Postmus et al. Nature Communications
- Correlation of PCSK9 Gene Polymorphism with Cerebral Ischemic Stroke in Xinjiang Han and Uygur Populations
- (2014) Jing Lei MEDICAL SCIENCE MONITOR
- PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum
- (2013) Thea Bismo Strøm et al. BIOCHEMICAL JOURNAL
- Association between PCSK9 and LDLR gene polymorphisms with coronary heart disease: Case-control study and meta-analysis
- (2013) Lina Zhang et al. CLINICAL BIOCHEMISTRY
- Proprotein Convertase Subtilisin/Kexin Type 9 Gene E670G Polymorphism Interacts with Alcohol Consumption to Modulate Serum Lipid Levels
- (2013) Lynn Htet Htet Aung et al. International Journal of Medical Sciences
- Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin andPCSK9Deficiency
- (2013) Kirill Tarasov et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
- (2013) Daniel Urban et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
- (2013) Janice Mayne et al. Lipids in Health and Disease
- Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population
- (2010) Ilaria Guella et al. JOURNAL OF LIPID RESEARCH
- PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
- (2010) Marianne Benn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles
- (2009) Giuseppe Danilo Norata et al. ATHEROSCLEROSIS
- Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels
- (2009) Chiang-Ching Huang et al. Circulation-Cardiovascular Genetics
- Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes
- (2009) Thea Bismo Strøm et al. CLINICA CHIMICA ACTA
- Healthy Individuals Carrying the PCSK9 p.R46L Variant and Familial Hypercholesterolemia Patients Carrying PCSK9 p.D374Y Exhibit Lower Plasma Concentrations of PCSK9
- (2009) S. E. Humphries et al. CLINICAL CHEMISTRY
- Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population
- (2008) Eliana Polisecki et al. ATHEROSCLEROSIS
- Molecular population genetics of PCSK9: a signature of recent positive selection
- (2008) Keyue Ding et al. Pharmacogenetics and Genomics
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More